Natera projected that expanded reimbursement for its minimal residual disease (MRD) assays will drive 2026 growth, confirming submissions to CMS MolDx for Latitude in colorectal cancer and additional filings for Signatera across indications. Management highlighted rising average selling prices and improving volumes tied to anticipated payer coverage expansion. Complementing commercialization trends, a multicenter study showed circulating tumor DNA (ctDNA) can guide FGFR‑targeted therapy decisions in metastatic urothelial cancer, strengthening the clinical utility argument for plasma‑based genotyping versus tissue. Together, payer movement and emerging prospective data support broader clinical adoption of tumor‑informed ctDNA testing for treatment selection and surveillance. Clinical note: Reimbursement and prospective evidence are central levers for ctDNA scale; companies with validated tumor‑informed assays are prioritizing MolDx and payer engagements to capture surveillance and adjuvant market opportunities.